Publication date: Apr 15, 2019
Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulating tumor DNA mutations versus primary tumor mutations. Remote sampling of circulating tumor DNA can serve as viable option in clinical diagnostics. Here, we discuss the progress toward broad adoption of liquid biopsy as a diagnostic tool and discuss knowledge gaps that remain to be addressed.
Muluhngwi, P., Valdes, R., Fernandez-Botran, R., Burton, E., Williams, B., and Linder, M.W. Cell-free DNA diagnostics: current and emerging applications in oncology. 22314. 2019 Pharmacogenomics.
- New liquid biopsy technique used to assess melanoma progression
- Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy.
- How Immunotherapy Is Improving Treatment for Melanoma
- Spatial intratumor heterogeneity in uveal melanoma: Tumor cell subtypes with a presumed invasive potential exhibit a particular epigenetic staining reaction.